Orexo AB (Sweden) Insiders
| ORX Stock | SEK 23.85 -0.15 -0.62% |
Orexo AB employs about 126 people. The company is managed by 9 executives with a total tenure of roughly 64 years, averaging almost 7.0 years of service per executive, having 14.0 employees per reported executive. For Orexo AB, management analysis can help investors test whether leadership decisions are reinforcing the broader investment thesis or creating new operating risk. The better read usually comes from comparing management claims with operating results, tenure stability, and capital-allocation outcomes over time.
| Nikolaj Sorensen CEO Pres CEO |
| Cecilia Coupland President Vice President and Head of Operations |
Orexo |
Management Team Effectiveness
The company has return on total asset (ROA) of -9.65 % suggesting that asset deployment is not yet covering its cost of capital. This trails well behind sector averages. Similarly, it shows a return on equity (ROE) of -65.35 %, meaning that equity holders received a negative return on their investment.Outstanding Bonds
Reviewing Orexo AB bond obligations helps investors understand how much of the business is financed with fixed-income capital rather than purely with equity. Maturity profile, refinancing windows, and coupon burden can all affect how resilient the capital structure looks in a weaker market.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Holders Distribution
A large institutional presence around Orexo AB deserves attention because well-resourced investors can establish or unwind positions quickly enough to change the market character of the security. The opportunity for retail investors is not to imitate blindly, but to understand how large-holder positioning may affect liquidity, volatility, and timing.
Workforce Comparison
Orexo AB earns the top ranking in number of employees relative to competitors. The total workforce of Health Care industry is now estimated at about 696. Orexo AB retains roughly 126 in number of employees claiming about 18% of equities under Health Care sector.
The company has Profit Margin (PM) of -28.0 %, which may reflect temporary margin compression under competitive pressure. This trails well behind sector averages. Similarly, it shows Operating Margin (OM) of -29.0 %, which entails that for every 100 dollars of sales, the company had a net operating shortfall of $29.0. Benchmark Summation
Operator |
This analysis covers sixty-one data points across the selected time horizon. Orexo AB Price Series Summation is a cross summation of Orexo AB price series and its benchmark/peer.
Notable Stakeholders
Reviewing the stakeholders around Orexo AB can help investors understand which people or institutions may influence direction, governance, and strategic pressure. This becomes more informative when investors want to understand not just ownership, but influence, incentives, and strategic pressure points.
| Nikolaj Sorensen | Pres CEO | Profile | |
| Cecilia Coupland | Vice President and Head of Operations | Profile | |
| Robert DeLuca | President of Orexo US Inc. | Profile | |
| Robert Ronn | Vice President and Head of Research & Development | Profile | |
| Fredrik Jarrsten | Ex CFO | Profile | |
| MD MBA | Chief Officer | Profile | |
| Lena Wange | Investor Relations & Communications Manager | Profile | |
| Jesper Lind | Advisor | Profile | |
| Dennis Urbaniak | Ex Therapeutics | Profile |
Management Information & Data Sources
Orexo AB is a small-cap company. Executive review focuses on insiders, senior management, and employee signals. Insider activity can provide context on alignment between management and outside holders. CEO is Nikolaj Sorensen with 126 employees and 9 reported executives.
Unless otherwise specified, data for Orexo AB is compiled from periodic company reporting and market reference feeds and standardized for comparability. Updates may occur throughout the day. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Investors reviewing Orexo AB can use workforce efficiency as another lens on execution, especially when comparing similar businesses in the same industry. The business is commonly classified in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry.
Orexo AB Manpower Efficiency
Return on Orexo AB Manpower
| Revenue Per Employee | 5M | |
| Revenue Per Executive | 69.4M | |
| Net Loss Per Employee | 1.5M | |
| Net Loss Per Executive | 20.4M | |
| Working Capital Per Employee | 4.4M | |
| Working Capital Per Executive | 61.4M |
Additional Tools for Orexo Stock Analysis
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Prophet Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |